Publications

5891 Results

SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab (IMC-A12) versus androgen deprivation alone for patients with new metastatic castration-sensitive prostate cancer

Authors
EY Yu;CM Tangen;C Higano;N Agarwal;SK Pal;A Alva;E Heath;ET Lam;S Gupta;M Lilly;Y Inoue;KN Chi;NJ Vogelzang;DI Quinn;H Li;H Cheng;H Plymate;MHA Hussain;IM Thompson
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 5006); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session;
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
S0925

Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer

Authors
HH Cheng;H Li;C Higano;C Tangen;N Agarwal;J Yan;N Vogelzang;MHA Hussain;IM Thompson;M Tewari;EY Yu
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 5017); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
S0925

Omega-3-fatty acids for aromatase inhibitor-induced musculoskeletal symptoms in women with early stage breast cancer (SWOG S0927)

Authors
D Hershman;J Unger;K Crew;S Dakhil;D Awad;H Greenlee;L Minasian;L Hansen;K Kaberle;D Lew;J Gralow;J Wade;F Meyskens;C Moinpour
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 9532); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S0927

A Phase II Study of MK-2206, an Allosteric Inhibitor of AKT as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer, a SWOG Cooperative Group Trial (S1005)

Authors
R Ramanathan;S McDonough;H Kennecke;S Iqbal;J Baranda;T Seery;H Lim;AF Hezel;G Vaccaro;CD Blanke
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 4041); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
S1005

US Intergroup Phase II Trial (SWOG S1108) of Alisertib, an Investigational Aurora A Kinase (AAK) Inhibitor, in Patients with Peripheral T-Cell Lymphoma (PTCL) (NCT01466881)

Authors
P Barr;H Li;C Spier;D Mahadevan;J Friedberg;M Leblanc;M Ul Haq;C Flowers;N Wagner-Johnston;SM Horwitz;B Cheson;TP Miller;RI Fisher
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 8523); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S1108

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of AromataseInhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer: SWOG S1202

Authors
NL Henry;J Unger;A Schott;L Hansen;D Lew;J Wade;C Moinpour;GN Hortobagyi;FL Meyskens
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS9662); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1202

SWOG 1211: a randomized phase I/II study of optimal induction therapy of bortezomib, dexamethasone and lenalidomide with or without elotuzumab for newly diagnosed high risk multiple myeloma (HRMM)

Authors
SZ Usmani;A Hoering;R Sexton;S Ailwahdi;JJ Shah;S Fredette;B Durie;J Zonder;M Dhodapkar;SV Rajkumar;T Zimmerman;P Richardson;RZ Orlowski
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS8624); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Myeloma
Study Number(s)
S1211

SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) + TAK-700 with ADT + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (HSPC) (NCT01809691)

Authors
N Agarwal;C Tangen;M Hussain;P Lara;C Higano;D Vaena;G MacVicar;H Li;T Cirspino;DI Quinn;N Vogelzang;IM Thompson
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS5102);ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients

Authors
P Blanchard;AMW Lee;J Leclercq;S Marquet;WT Ng;J Ma;ATC Chan;P Huang;G Zhu;DTT Chua;HQ Mai;J Wee;DLW Kwong;J Moon;KH Chi;G Fountzilas;M Hareyama;L Zhang;J Bourhis;J-P Pignon
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 6022); ASCO (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817)

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa)

Authors
LA Carey;WT Barry;B Pitcher;K Hoadley;MCU Cheang;IE Krop;NL Henry;DA Berry;CM Perou;EP Winer;CA Hudis
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 506); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session;
Year
2014
Research Committee(s)
Breast